Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.

Expert opinion on therapeutic targets - 1 Mar 2021

Morsia Erika, Gangat Naseema

Abstract excerpt

Introduction: Myelofibrosis (MF) is characterized by anemia, splenomegaly, constitutional symptoms and bone marrow fibrosis. MF has no curative treatment to date, except for a small subset of patients that are eligible for allogeneic hematopoietic stem cell transplant. The discovery in recent years of the MF mutational landscape and the role of bone marrow microenvironment in disease pathogenesis has led to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Development
Share to Genomics
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Molecular Targeted Therapy

Share to Precision Medicine

Share to Primary Myelofibrosis

Source

Identifiers

PMID: 33844952
DOI: 10.1080/14728222.2021.1915992

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.PMID 33844952Read ↗

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives.Semantic proximity Read ↗

Management of Myelofibrosis: from Diagnosis to New Target Therapies.Semantic proximity Read ↗

Myelofibrosis: an update on current pharmacotherapy and future directions.Semantic proximity Read ↗

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and TreatmentsSemantic proximity Read ↗

Myelofibrosis biology and contemporary management.Semantic proximity Read ↗

Biological drivers of clinical phenotype in myelofibrosis.Semantic proximity Read ↗

Novel therapies for myelofibrosis.Semantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?Semantic proximity Read ↗

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.Semantic proximity Read ↗

How I treat myelofibrosis.Semantic proximity Read ↗

The Role and Impact of Non-driver Gene Mutations in Myelofibrosis.Semantic proximity Read ↗

Allogeneic stem cell transplantation for myelofibrosis in 2012.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.